Citigroup’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-1,872
| Closed | -$7.34K | – | 5111 |
|
|
2023
Q3 | $7.34K | Buy |
1,872
+1,777
| +1,871% | +$6.97K | ﹤0.01% | 3905 |
|
|
2023
Q2 | $309 | Buy |
95
+33
| +53% | +$107 | ﹤0.01% | 4649 |
|
|
2023
Q1 | $226 | Sell |
62
-4,919
| -99% | -$17.9K | ﹤0.01% | 4518 |
|
|
2022
Q4 | $160K | Buy |
4,981
+4,674
| +1,522% | +$151K | ﹤0.01% | 3147 |
|
|
2022
Q3 | $13K | Buy |
307
+210
| +216% | +$8.89K | ﹤0.01% | 4184 |
|
|
2022
Q2 | $4K | Sell |
97
-16
| -14% | -$660 | ﹤0.01% | 4957 |
|
|
2022
Q1 | $8K | Sell |
113
-355
| -76% | -$25.1K | ﹤0.01% | 4859 |
|
|
2021
Q4 | $57K | Buy |
468
+181
| +63% | +$22K | ﹤0.01% | 4233 |
|
|
2021
Q3 | $40K | Buy |
287
+215
| +299% | +$30K | ﹤0.01% | 4124 |
|
|
2021
Q2 | $20K | Sell |
72
-4
| -5% | -$1.11K | ﹤0.01% | 4634 |
|
|
2021
Q1 | $16K | Sell |
76
-104
| -58% | -$21.9K | ﹤0.01% | 4718 |
|
|
2020
Q4 | $44K | Buy |
180
+132
| +275% | +$32.3K | ﹤0.01% | 4181 |
|
|
2020
Q3 | $5K | Sell |
48
-56
| -54% | -$5.83K | ﹤0.01% | 4702 |
|
|
2020
Q2 | $10K | Sell |
104
-80
| -43% | -$7.69K | ﹤0.01% | 4651 |
|
|
2020
Q1 | $14K | Buy |
184
+46
| +33% | +$3.5K | ﹤0.01% | 4525 |
|
|
2019
Q4 | $11K | Buy |
138
+43
| +45% | +$3.43K | ﹤0.01% | 4698 |
|
|
2019
Q3 | $12K | Sell |
95
-84
| -47% | -$10.6K | ﹤0.01% | 4505 |
|
|
2019
Q2 | $32K | Sell |
179
-22
| -11% | -$3.93K | ﹤0.01% | 4372 |
|
|
2019
Q1 | $32K | Buy |
201
+6
| +3% | +$955 | ﹤0.01% | 4314 |
|
|
2018
Q4 | $51K | Buy |
195
+121
| +164% | +$31.6K | ﹤0.01% | 3906 |
|
|
2018
Q3 | $18K | Buy |
74
+35
| +90% | +$8.51K | ﹤0.01% | 4560 |
|
|
2018
Q2 | $9K | Buy |
+39
| New | +$9K | ﹤0.01% | 4653 |
|